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Paliperidone palmitate is a long-acting injectable
antipsychotic indicated for the treatment of schizophrenia
and schizoaffective disorders in adults. Once tolerability is
established with oral paliperidone, the recommended
initiation dose of paliperidone palmitate is 234 mg on day
one and 156 mg one week later. The recommended
administration location for these two initiation doses are in
the deltoid muscle because administration in the deltoid
muscle has an average maximum concentration that is 28%
higher compared to the gluteal muscle. These two initiation
doses aid to reach therapeutic concentrations rapidly. The
monthly maintenance doses can be administered either in
the gluteal or deltoid location. The variance in the location
of administration can result in a lower blood concentration
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The purpose of this study was to evaluate the administration
location of paliperidone palmitate initiation doses in an
acute behavioral unit at The University of Texas Health North
Campus Tyler. The results will be used to improve
paliperidone palmitate administration procedures if
necessary
Methods
A list of patients who have received paliperidone palmitate
at The University of Texas Health North Campus Tyler from
January 1, 2018 to June 15, 2020 was gathered from
pharmacy records. Study inclusion criteria included all
patients over 18 years of age who received paliperidone
palmitate on the acute behavioral health unit and received
oral paliperidone palmitate during hospitalization prior to
the initiation dose of paliperidone palmitate. Patients were
excluded if they were less than 18 years of age, were
hospitalized on another unit of the hospital, or did not
receive oral paliperidone prior to the paliperidone palmitate
injection.
Using the visit number, researchers accessed the patients’
electronic medical record. Name and date of birth were used to
confirm the correct chart was accessed. For all included
patients, the location of injection for each paliperidone dose
was collected and recorded as either gluteal or deltoid and
either left or right side. The location of the doses (side and
muscle) was then put into a deidentified Excel document. Once
the data was collected, descriptive statistics were used to
describe the results. This study was approved by the IRB at the
University of Texas Health Science Center at Tyler.
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Thirty-seven patients were evaluated for the study inclusion. 
Three patients were excluded due to hospitalization on another 
unit and nine patients were excluded because they did not 
receive an oral dose of paliperidone before the paliperidone 
injection. A total of twenty-five patient were included in the 
study. Twenty-four patients received the 234mg dose of 
paliperidone palmitate and eighteen patients received the 
156mg dose of paliperidone palmitate. Eight of the 234mg 
doses were given in the gluteal muscles (33%) and 12 of the 
156mg doses were given in the gluteal muscle (66%). 
Graph 1: Injection location of 234 mg  dose. 
Conclusion
Although the initiation doses of paliperidone palmitate
should be administered in the deltoid muscle to achieve
therapeutic concentrations rapidly, 33% of the 234mg doses
and 66% of the 156mg doses were given in the gluteal
muscle on this acute behavioral health unit. The results of
this study will be used to provide nursing education on
appropriate administration of the paliperidone palmitate
initiation doses. In addition, medication label changes that
specify specific administration location for paliperidone
palmitate initiation doses will be pursued.
Methods (Continued)
Graph 2: Injection location of the 156 mg dose.
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